FDA Warns Against Morcellation for Uterine Fibroids

Share this content:
FDA Warns Against Morcellation for Uterine Fibroids
FDA Warns Against Morcellation for Uterine Fibroids

(HealthDay News) — Laparoscopic power morcellation for treatment of fibroids could increase a woman's risk of cancer, the U.S. Food and Drug Administration warned Thursday.

The FDA said that the procedure can inadvertently spread cancerous tissue beyond a woman's uterus and into other parts of her body. 

The FDA estimates that about one in 350 women undergoing a hysterectomy or fibroid removal has an unsuspected uterine sarcoma. If a surgeon performs power morcellation on these women, there's a risk the procedure will spread the cancerous tissue within the patient's abdomen and pelvis.

RELATED: Excessive Uterine Leiomyosarcoma Dissemination Risk During Uterine Morcellation

The FDA stopped short of banning the power morcellation device from the market, but is urging physicians and patients to weigh the risk prior to its use. About 60,000 of these procedures are performed every year, said William Maisel, MD, MPH, deputy director for science and chief scientist at the FDA's Center for Devices and Radiological Health at a Thursday news conference.

Women who already have undergone power morcellation don't need to get a cancer screening, because some of the tissue removed during the procedure would have been sent for pathologic analysis, Maisel said at the news conference. If cancer had been detected, they would have been informed, he added. 

"We think that most women who have undergone these procedures require routine care," he said. "If they don't have any ongoing or recurrent symptoms, they should be fine."

Read more here.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs